Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): CAN10

            Therapeutic Area: Dermatology Product Name: CAN10

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Cantargia AB

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement November 26, 2020

            Details:

            CAN10 is fully humanized monoclonal antibody targeting IL1RAP. BioInvent will provide process development, scale-up, supply of material for toxicological studies and clinical grade material in 1000L scale for use in phase I and II clinical trials.